Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Temporarily Stiffened Mesh Prostheses

a technology of mesh prosthesis and mesh, which is applied in the field of medical prosthesis, can solve the problems of hernias, excessive scar tissue formation, and antibiotics that are effective at preventing implant-related infections

Inactive Publication Date: 2009-01-15
TYRX
View PDF51 Cites 48 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

"The present invention is about a medical prosthesis that includes a mesh with a coating that temporarily stiffens the mesh. The coating can be applied to the mesh without changing its integrity and allows the mesh to remain porous. The stiffening agents used in the coating can selectively, partially, or fully coat the contact points of the mesh filaments or fibers. The coatings can also contain drugs that can be released over time to prevent complications associated with implantation or surgery. The coated mesh can be used to securely hold implantable devices in place, provide pain relief, inhibit scarring or fibrosis, and prevent bacterial growth. The invention also provides a method for delivering drugs at controlled rates and for set durations of time using biodegradable polymers."

Problems solved by technology

However, such devices are often associated with post-surgical complications including post-implant infection, pain, excessive scar tissue formation and shrinkage of the prosthesis or mesh.
Patients will occasionally be given systemic antibiotics prophylactically; however, literature review of clinical trials does not indicate that systemic antibiotics are effective at preventing implant-related infections.
Hernias usually occur because of a natural weakness in the abdominal wall or from excessive strain on the abdominal wall, such as the strain from heavy lifting, substantial weight gain, persistent coughing, or difficulty with bowel movements or urination.
Tightly woven meshes with the highest strength characteristics and stiffness are very easy for the surgeon to implant; however, there appears to be a positive correlation between the tightness of the weave (correlated to surface area and stiffness), lack of patient mobility, and chronic pain.
Newer meshes have larger pore structures and while they are more flexible, they are also more difficult to implant by surgeons.
They are extremely difficult for laparoscopic repair, as they have very little recoil associated with them and, when rolled up to insert, they cannot be reflattened and positioned in a quick and efficient manner by the surgeon.
Surgical meshes that have been manipulated to improve handling, insertion and positioning post-insertion are known in the art, but do not employ larger-pore mesh construction.
For example, a laparoscopic surgical mesh with extruded monofilament PET coils or rings (e.g., the Bard® Composix® Kugel® hernia patch) increases the overall stiffness of the device and gives a shape memory to the device but does not readily allow for drug loading of the mesh, can not provide temporary stiffening of the mesh component, and can not be further shaped into a fixed three-dimensional structure after manufacture without further processing or alteration.
These meshes have the same disadvantages as those with coils or rings.
Additionally, the Kugel patch ring has been reported to break under conditions of use, causing patient morbidity and mortality.
Moreover, because the biodegradable polymers of that mesh may be subjected to high temperatures to produce fibers and filaments suitable for weaving, it drastically limits the drugs or biologically active agents that can be included in a biodegradable layer since, under such conditions, the vast majority of biologically-active agents and drugs are unable to withstand the manufacturing temperatures involved in fiber and filament formation.
Finally, these meshes are often more difficult for surgeons to anchor in place because the polyglactin fiber cannot withstand the suturing tension.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Temporarily Stiffened Mesh Prostheses
  • Temporarily Stiffened Mesh Prostheses
  • Temporarily Stiffened Mesh Prostheses

Examples

Experimental program
Comparison scheme
Effect test

example 1

Antibiotic Release from DTE-DT succinate Coated Mesh

[0080]A. Preparation of mesh by spray-coating

[0081]A 1% solution containing a ratio of 1:1:8 rifampin:minocycline:polymer in 9:1 tetrahydrofuran / methanol was spray-coated onto a surgical mesh by repeatedly passing the spray nozzle over each side of the mesh until each side was coated with at least 10 mg of antimicrobial-embedded polymer. Samples were dried for at least 72 hours in a vacuum oven before use.

[0082]The polymers are the polyarylates P22-xx having xx being the % DT indicated in Table 1. In Table 1, Rxx or Mxx indicates the percentage by weight of rifampin (R) or minocycline (M) in the coating, i.e., R10M10 means 10% rifampin and 10% minocycline hydrochloride with 80% of the indicated polymer. Table 1 provides a list of these polyarylates with their % DT content, exact sample sizes, final coating weights and drug coating weights.

TABLE 1Polyarylate Coated Meshes with Rifampin and Minocycline HClAvg. CoatingCoating Wt.Sampl...

example 2

Bupivacaine Release from DTE-DT Succinate Coated Mesh

A. Preparation of Mesh

[0087]For the experiment shown in FIG. 2, a first depot coating containing 540 mg of bupivacaine HCl as a 4% solution with 1% P22-27.5 polyarylate in a mixture of THF Methanol was spray coated onto a mesh. A second layer consisting of 425 mg of the same polyarylate alone was deposited on top of the first layer.

[0088]For the experiment shown in FIG. 3, a solution of approximately 4% bupivacaine in DTE-DT succinate polymer having 27.5% DT was sprayed onto a mesh using the indicted number of passes followed by the indicated number of dips into a solution of the same polyarylate in THF:Methanol (9:1)

B. Anesthetic Release

[0089]Pre-weighed pieces of mesh were placed in PBS at 37° C. and a sample withdrawn periodically for determination of bupivacaine by HPLC. FIG. 2 shows the cumulative release of bupivacaine into PBS from the multilayer polyarylate coating as a function of time. Nearly 80% of the bupivacaine had b...

example 3

In Vivo Bupivacaine Release from DTE-DT succinate coated Meshes

A. Overview

[0091]Rats with jugular cannulas for pharmacokinetic studies were surgically implanted with a 1×2 cm P22-27.5 polyarylate-coated mesh containing 7.5 mg of bupivacaine / cm2. Before surgery, baseline pin-prick responses to nociception were measured at the planned surgical incision site, and baseline blood samples were obtained. A hernia was created by incision into the peritoneal cavity during via subcostal laparotomy, and a Lichtenstein non-tension repair was performed using the bupivacaine-impregnated polyarylate-coated mesh. Blood samples were drawn at 3, 6, 24, 48, 72, 96, and 120 hours after implantation. Prior to drawing blood, the rats were subjected to a pin prick test to assess dermal anesthesia from bupivacaine release. The behavioral results indicate that moderate levels of dermal anesthesia appeared from 3 to 120 hours, with the amount at 6 and 48 hours significantly above baseline (p<0.05). Pharmacok...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
flow rateaaaaaaaaaa
surgical timeaaaaaaaaaa
surgical timeaaaaaaaaaa
Login to View More

Abstract

The present invention relates to medical prostheses and methods of manufacturing those devices. In particular, the prostheses are temporarily stiffened meshes with particular coatings to provide initial stiffness and thereby permit easier surgical handling for treatment or reconstruction of soft tissue defects. Preferred embodiments include surgical meshes coated with one or more biodegradable polymers that can act as a stiffening agent by coating the filaments or fibers of the mesh to temporarily immobilize the contact points of those filaments or fibers and / or by increasing the stiffness of the mesh by at least 1.1 times its original stiffness. The devices of the invention can also provide relief from various post-operative complications associated with their implantation, insertion or surgical use. By including biologically active agents and / or drugs in the coating, the devices provide prophylaxis for and can alleviate side effects or complications associated with the surgery or use of prostheses in general.

Description

[0001]This application is a continuation of U.S. Ser. No. 11 / 672,929, filed Feb. 8, 2007, which claims priority under 35 U.S.C. § 119(e)(5) of U.S. Provisional Patent Application No. 60 / 864,597, filed Nov. 6, 2006 and U.S. Provisional Patent Application No. 60 / 772,827, filed Feb. 8, 2006, which are incorporated herein by reference.FIELD OF THE INVENTION[0002]The present invention relates to medical prostheses and methods of manufacturing those devices. In particular, the prostheses are temporarily stiffened meshes with particular coatings to provide initial stiffness and thereby permit easier surgical handling for treatment or reconstruction of soft tissue defects. Preferred embodiments include surgical meshes coated with one or more biodegradable polymers that can act as a stiffening agent by coating the filaments or fibers of the mesh to temporarily immobilize the contact points of those filaments or fibers and / or by increasing the stiffness of the mesh by at least 1.1 times its o...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61B17/08A61F2/02
CPCA61F2/0063A61F2210/0004A61F2250/0067A61L31/10A61L31/146A61L31/148A61L27/34A61L2300/402A61L2300/404A61L2300/416A61L2300/45A61L2300/606A61L31/16A61F2310/0097A61P23/02A61P31/00A61L27/54A61L27/56A61L27/58A61L2300/406A61L2430/02
Inventor BUEVICH, FATIMADO, FRANKMCJAMES, WILLIAMPULAPURA, SATISHEDELMAN, WILLIAMMOSES, ARIKHADIAMOND, MASONTIMOTHY, SHARI
Owner TYRX
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products